John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Pead E, Megaw R, Cameron J, Fleming A, Dhillon B, Trucco E, MacGillivray T. Automated detection of age-related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019 Jul 1;64(4):498-511. doi: 10.1016/j.survophthal.2019.02.003
Saigi-Morgui N, Quteineh L, Bochud PY, Crettol S, Kutalik Z, Mueller NJ, Binet I, Van Delden C, Steiger J, Mohacsi P, Dufour JF, Soccal PM, Pascual M, Eap CB, Swiss Cohort Study. Genetic and clinic predictors of new onset diabetes mellitus after transplantation. Pharmacogenomics J. 2019 Feb;19(1):53-64. doi: 10.1038/s41397-017-0001-5
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Brown JP, Amaechi BT, Bader JD, Shugars D, Vollmer WM, Chen C, Gilbert GH, Esterberg EJ, X-ACT Collaborative Research Group. The dynamic behavior of the early dental caries lesion in caries-active adults and implications. Community Dent Oral Epidemiol. 2015 Jun;43(3):208-16. doi: 10.1111/cdoe.12143
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.